Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment
Neurology, Volume 80, No. 2, Year 2013
Notification
URL copied to clipboard!
Description
Objective: To evaluate the efficacy and safety of minocycline in the management of HIV-associated cognitive impairment. Methods: We enrolled HIV-positive participants with a CD4 count of 250 to 500 cells/μL in a randomized, double-blind, placebo-controlled study. They received 100 mg of minocycline or matching placebo orally every 12 hours for 24 weeks. Cognitive function was measured using the Uganda Neuropsychological Test Battery Summary Measure (U NP Sum) and the Memorial Sloan-Kettering (MSK) scale. The primary efficacy measure was the 24-week change in an average of 9 standardized U NP Sum z scores. Results: Seventy-three participants were enrolled. Of these, 90% were female, 49% were between the ages 30 and 39 years, and 74% had 6 or more years of education. One participant had MSK score of stage 1 (i.e., mild HIV dementia), and 72 participants had MSK stage 0.5 (i.e., equivocal or subclinical dementia) at the baseline evaluation. The minocycline effect on the 24-week change of the U NP Sum compared with placebo was 0.03 (95% confidence interval-0.51, 0.46; p = 0.37). Conclusion: Minocycline was safe and well tolerated in HIV-positive individuals. However, it did not improve HIV-associated cognitive impairment. Classification of evidence: This study provides Class II evidence that 100 mg of minocycline given orally every 12 hours for 24 weeks had no significant effect compared with placebo in the improvement of cognitive function in antiretroviral therapy-naive, HIV-positive patients. © 2013 American Academy of Neurology.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3589188/bin/supp_80_2_196__index.html
https://efashare.b-cdn.net/share/pmc/articles/PMC3589188/bin/supp_WNL.0b013e31827b9121_Randomized_trial_of_Monocycline.pdf
Authors & Co-Authors
Nakasujja, Noeline
Uganda, Kampala
Makerere University
Miyahara, Sachiko
United States, Boston
Harvard T.h. Chan School of Public Health
Evans, Scott R.
United States, Boston
Harvard T.h. Chan School of Public Health
Lee, Anthony J.
United States, Boston
Harvard T.h. Chan School of Public Health
Musisi, Seggane M.
Uganda, Kampala
Makerere University
Katabira, Elly Tebasoboke
Uganda, Kampala
Makerere University
Robertson, Kevin R.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
Ronald, Allan R.
Canada, Winnipeg
University of Manitoba
Clifford, David B.
United States, St. Louis
Washington University in St. Louis
Sacktor, Ned Charlton
United States, Baltimore
Johns Hopkins School of Medicine
Statistics
Citations: 59
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1212/WNL.0b013e31827b9121
ISSN:
00283878
e-ISSN:
1526632X
Research Areas
Disability
Infectious Diseases
Mental Health
Study Design
Case-Control Study
Study Locations
Uganda
Participants Gender
Female